Retatrutide Food and Supplement Interactions: The Study Map

First Define the Product

FDA's current warning page is categorical:

“Retatrutide and cagrilintide cannot be used in compounding under federal law.”

The issuer is the U.S. Food and Drug Administration. The excerpt addresses federal compounding eligibility; it does not describe every interaction, endorse a product, or convert trial findings into personal instructions (FDA unapproved GLP-1 notice).

That boundary matters because an interaction result belongs to the substance, formulation, amount, and route actually studied. A seller's “retatrutide” vial cannot inherit the sponsor product's evidence merely by sharing a name.

The Interaction Study Map

What the Metoprolol Study Adds

ClinicalTrials.gov record NCT06808802 describes a completed Phase 1, open-label, single-arm study of retatrutide's effect on oral metoprolol pharmacokinetics. Thirty healthy adults ages 21–65 received metoprolol before and after subcutaneous retatrutide exposure. The study completed in 2025, but the registry had no results section on August 30, 2026 (NCT06808802).

This record is useful because it shows what a real interaction question looks like: named products, a defined sequence, measured exposure, and a specified population. It does not establish the answer before results are posted, and it does not generalize to every oral medicine or supplement.

Food Is Context, Not an Absorption Instruction

The Phase 2 obesity trial delivered retatrutide by once-weekly subcutaneous injection under a controlled protocol (PMID 37366315; DOI 10.1056/NEJMoa2301972). A meal does not encounter an injection in the gastrointestinal tract as it would an oral tablet.

Food can still matter clinically through nutrition, glucose, hydration, symptoms, or another oral medicine. But those are separate questions. The legacy page's lists of foods to avoid, protein targets, electrolyte schedules, vitamin additions, and alcohol timing were not retatrutide interaction-study results.

The young-adult safety audit maps observed adult events without inventing a subgroup protocol. The older-adult safety page handles population transfer, and the pregnancy and lactation review explains why comparator labels cannot create retatrutide-specific instructions.

Why Mechanism Does Not Set a Spacing Interval

Even if retatrutide changes gastric emptying, a clinically important effect on an oral medicine depends on that medicine's formulation, absorption window, therapeutic range, and the timing and magnitude of the effect. “Separate by two hours” is not a universal solution, and no approved retatrutide label supplies one.

Likewise, a supplement's separate effect on glucose, appetite, or gastrointestinal symptoms cannot establish synergy or harm when combined. Direct coadministration evidence would need characterized products, exposure timing, PK or pharmacodynamic outcomes, and adverse-event collection.

The Responsible Bottom Line

The evidence supports a study map, not an interaction chart. Retatrutide remains investigational; one named oral-drug PK question has been studied without posted results, while direct food, alcohol, and supplement combinations remain uncharacterized.

Anyone in a legitimate trial should route medication and supplement questions to the study team, which has the protocol and investigator brochure. Outside a trial, an online timing plan cannot substitute for an approved product, known exposure, or interaction evidence.

Medical review of this revision is pending. FDA, ClinicalTrials.gov, sponsors, investigators, institutions, and study authors do not endorse retatrutide, HealthRX.com, or this page.